A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

Vaccine

Volumn 19, Issue 23-24, 2001, Pages 3033-3042

  Lambert, John S ^a,j   Keefer, Michael ^b   Mulligan, Mark J ^c   Schwartz, David ^d   Mestecky, Jiri ^e   Weinhold, Kent ^f   Smith, Carol ^g   Hsieh, Ray ^g   Moldoveanu, Zina ^e   Fast, Patricia ^h   Forrest, Bruce ⁱ   Koff, Wayne ⁱ  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham Heersink School of Medicine   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e University of California   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g EMMES CORPORATION   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ United Biomedical Inc   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

HIV; Mucosal immunity; Vaccines

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MICROSPHERE; POLYGLACTIN; PROTEIN MN V3; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; ENCAPSULATION; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; AIDS VACCINES; ALUMINUM HYDROXIDE; ANTIBODY-PRODUCING CELLS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MALE; MICROSPHERES; MIDDLE AGED; PEPTIDE FRAGMENTS; SAFETY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035972026     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00051-2     Document Type: Article

References (39)

1. The emergence of simian/human immunodeficiency viruses
2. Pathogenesis of human immunodeficiency disease virus infection
3. Development and testing of AIDS vaccines
4. HIV vaccines
5. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview
6. Human trials of HIV-1 vaccines
7. The mucosal immune system: From fundamental concepts to vaccine development
8. Mucosal vaccines - An overview
9. Women, HIV and mucosal immunity
10. Biology of disease: Mucosal immunity, HIV transmission and AIDS
11. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen
12. Poly (Lactide-Co-Glycolide) microencapsulation of vaccines for mucosal immunization
13. Antigen delivery systems. Nonliving microparticles, liposomes, cochleates, and ISCOMS
14. Protection against vaginal SIV transmission with microencapsulated vaccine
15. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine
16. Safety and immunogenicity of UBI® HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection
17. I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. International clinical trials of HIV vaccines
18. II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. International clinical trials of HIV vaccines
19. Long-term high-titer neutralizing activity influenced by octameric synthetic HIV-1 antigen
20. Induction of high-titer persistent neutralizing antibodies by HIV-1 V3 octa-branched peptides
21. A novel method for producing anti-peptide antibodies
22. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
23. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide
24. The safety and immunogenicity of human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans
25. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in low-risk volunteers
26. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
27. Phenotypic variation in response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines
28. Induction of HIV-1-neutralization and syncytium-inhibiting antibodies in uninfected recipients of HIV-1mn rgp120 subunit vaccine
29. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4
30. Immunoglobulin A (IgA)
31. Assay of human IgA subclass antibodies in serum and secretions by means of monoclonal antibodies
32. NIAID AIDS Vaccine Clinical Trials Network. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160
33. Isolation of mononuclear cells and granulocytes from human blood
34. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses
35. Human T-cell lymphotropic virus-IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells as target for immune attack
36. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells
37. Antigen delivery systems: New approaches to mucosal immunization